Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)

The three part, double‐blind, randomized, controlled reSURFACE 1 trial and extension study (NCT01722331) evaluated efficacy and safety of tildrakizumab in adults with moderate to severe plaque psoriasis. Patients with ≥50% improvement from baseline in Psoriasis Area and Severity Index (PASI 50) foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Imafuku, Shinichi, Nakagawa, Hidemi, Igarashi, Atsuyuki, Morita, Akimichi, Okubo, Yukari, Sano, Shigetoshi, Tada, Yayoi, Nemoto, Osamu, Rozzo, Stephen J., Kawamura, Masaki, Ohtsuki, Mamitaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248015/
https://www.ncbi.nlm.nih.gov/pubmed/33523513
http://dx.doi.org/10.1111/1346-8138.15763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248015/
https://www.ncbi.nlm.nih.gov/pubmed/33523513
http://dx.doi.org/10.1111/1346-8138.15763

Ejemplares similares